Program Description
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) remain leading causes of vision loss and cause substantial quality of life burden among older adults. The same pathways involving vascular endothelial growth factor (VEGF) and angiopoietin-2 (ang-2) contribute to the development of nAMD and DME and have become treatment targets. However, disease management with VEGF inhibitors and monoclonal antibody therapies require frequent intravitreal injections, which can limit patient access to therapy and impact treatment affordability. This supplement to The American Journal of Managed Care® will review new formulations and advancements in nAMD and DME aimed at addressing these treatment burdens to improve patient adherence and outcomes. Real-world evidence will be examined to highlight opportunities for managed care pharmacists to best incorporate new and emerging intravitreal treatment options into management plans for patients with nAMD and DME to reduce health care resource utilization and direct medical costs.
Target Audience: Managed care pharmacists
Type of Activity: Application
Release date: April 28, 2023
Expiration date: June 14, 2024
Time to complete activity: 3.0 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the disease and treatment burden that impact quality of life and visual outcomes for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
- Investigate the efficacy and safety data for emerging therapies and various treatment approaches for nAMD and DME
- Identify the best practices for managed care professionals to integrate the latest data and advances in treatment to improve outcomes for patients with nAMD and DME
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
